



# Interim Report Q1 2025



# Contents

Interim Report Q1 2025 ..... 1

From Transformation to Integration ..... 2

Highlights First Quarter 2025 results ..... 3

Key Figures..... 4

First Quarter Financial Review..... 5

Balance Sheet ..... 6

Cash Flow ..... 7

Market Review ..... 8

Focus on Integrating dsm–firmenich’s Marine Lipids business ..... 10

Governance and Compliance..... 11

Financial Statements ..... 12

    A.    Unaudited consolidated statement of financial positions as of Q1  
          2025<sup>1</sup> ..... 13

    B.    Unaudited consolidated statement of comprehensive income Q1  
          2025<sup>2</sup> ..... 15

    C.    Unaudited consolidated statement of changes in equity period Q1  
          2025<sup>3</sup> ..... 17

    D.    Unaudited consolidated statement of cash flows period Jan. 1, 2025  
          to Mar. 31, 2025<sup>4</sup>..... 18

    E.    Notes to the condensed unaudited consolidated financial statements  
          for the period Jan. 1, 2025 to Mar. 31, 2025..... 20

        E.I General information..... 20

        E.II Significant accounting and valuation methods..... 20

        E.III Consolidation..... 22

        E.IV Notes on individual items in the consolidated financial statement ... 22

        E.V Notes on individual items in the income statement ..... 26

E.VI Statement of cash flows ..... 29

E.VII Financial instruments..... 29

E.VIII Segment reporting ..... 30

E.IX Related party disclosure ..... 33

E.X Events after the reporting period ..... 34

Risk Factors..... 35

## From Transformation to Integration

Dear Stakeholders,

Following our transformational journey in 2024, we began 2025 fully focused on integrating and consolidating our newly expanded organization. I'm pleased to share several key updates on the progress we've made in the first quarter.

Firstly, we have initiated the consolidation of our manufacturing footprint, optimizing our operations across our global production network. This crucial step sets the foundation for capturing synergies and enhancing our competitive positioning in the omega-3 market.

We have also advanced considerably in the carve-out and integration of our processes and systems from the acquired Marine Lipids business. While meaningful progress has been achieved, we recognize significant work still lies ahead to fully harmonize our integrated systems and maximize operational efficiency.

Furthermore, we successfully finalized the year-end audit process, which unfortunately took longer than we had anticipated. Having this finalized now is an important milestone that positions us to prepare for our anticipated listing on the regulated market of the Oslo Stock Exchange later this year. This move will further solidify our market standing and broaden our investor base.

I would like to take this opportunity to thank our customers for their continued partnership and confidence as we navigate the integration process. Your collaboration in this enlarged business setting is invaluable, and we remain committed to providing exceptional service and innovation.

To our employees, thank you for your tremendous dedication and hard work during this intensive integration phase. Your resilience and commitment drive our success, and I am deeply grateful for your efforts.

Finally, to our investors, thank you for your continued trust and steadfast commitment. Your support is vital as we work through the integration phase to deliver on our strategic vision.

We are excited about the journey ahead and remain firmly committed to creating value for all our stakeholders.

Oscar Groet  
Chief Executive Officer  
KD Pharma Group



## Highlights First Quarter 2025 results

- Revenues reached 74m in Q1 2025, indicating a pick-up against Q4 2024 which represented the first quarter in the acquired dsm-firmenich customer/product portfolio was part of the KD Group.
- Adjusted EBITDA in Q1 amounted to € 10m, which was a notable increase also versus the last quarter as the integration of the acquired business progresses further.
- Net cash inflow for the quarter was € 5m, reflecting positive cash from operating activities with stable Trade Working Capital, as well as another tranche of a subordinated Shareholder Loan that was granted by dsm-firmenich to the KD Pharma Group as part of the transaction.
- Cash and cash equivalents at the end of the first quarter reached € 33m, with Net Interest-Bearing debt at € 157m.



## Key Figures

		Qtr1 2025	Qtr1 2024 Reported	Pro-forma Qtr1 2024		Qtr4 2024
				Pro-forma adj.	Combined	
<b>Net Sales</b>	<b>k€</b>	<b>73,631</b>	<b>53,373</b>	<b>39,431</b>	<b>92,804</b>	<b>47,909</b>
Pharma	k€	6,939	19,654	6,332	25,986	3,584
Nutra	k€	66,692	33,719	33,099	66,818	44,326
<b>Adjusted EBITDA</b>	<b>k€</b>	<b>10,014</b>	<b>7,990</b>	<b>11,041</b>	<b>19,031</b>	<b>2,026</b>
Adjusted EBITDA %	%	14%	15%		21%	4%
Net Interest Bearing Debt	k€	156,513	142,264		142,264	161,894
Cash and cash equivalents end of period	k€	33,484	21,044		21,044	28,906

### Notes:

Pro Forma figures reflect the Q1-Q3 2024 unaudited dsm-firmenich management accounts including carve-out and due diligence adjustments.

They are presented for illustrative purposes only, subject to change and not necessarily indicative of the actual results of operations.

2024 figures updated to the final audited accounts and may differ from the Q4 2024 Interim Report.

## First Quarter Financial Review

Revenues reached € 74m in Q1, which is 54% above previous quarter. Sales also increased versus the last year reported Q1 levels as a result of the acquisition of the dsm-firmenich Marine Lipids business. On a pro-forma basis, sales were below last year due to lower Pharma sales.

Sales in the Pharma segment in Q1 2025 almost doubled versus an unusually slow last quarter. Still compared to a relatively strong first quarter last year, sales in the Pharma segment are trailing. The Pharma market faced strong headwinds in 2024 after a period of rapid expansion, and recovery will likely be gradual. Main Key players in this segment are actively repositioning themselves to capture a share in the Omega-3 pharmaceutical market, we believe we are well positioned to serve these customers with superior offerings as the market demand picks up again.

Sales in the Nutra segment remained robust, and we saw sales in the Nutra marine lipids` portfolio acquired from dsm-firmenich clearly picking up after the slow start up last quarter, as expected. Sales in the segment in Q1 were on par with last year's pro-forma levels. Further progress is being made towards supplying customers in several countries which in part continue to be supplied by dsm-firmenich for some period of time, as the transfer of these customers require further carve out and transfer of certain registrations and licenses that could only be started after closing.

Adjusted EBITDA in the First Quarter amounted to € 10m, reflecting the positive sales developments versus last quarter. The lower sales in the Pharma segment versus Q1 2024 does impact the EBITDA performance versus the pro-forma Q1 2024 results.

In Q1, fixed costs were at par with pro-forma Q1 2024 levels. The consolidation of manufacturing at KD Pharma Group's enlarged Site network after the acquisition of the dsm-firmenich`s manufacturing sites is progressing. With the goal to bring down operational costs by streamlining production in fewer sites, the company aims to enhance efficiency, reduce operational complexity, and drive cost savings.

Our cash position at the end of the quarter stood at € 33m, a € 5m cash inflow for the quarter. It reflects positive cash from operating activities with Trade Working Capital remaining stable versus last quarter. Another tranche of a subordinated Shareholder Loan that was granted by dsm-firmenich to the KD Pharma Group as part of the transaction also contributed to the cashflow.

With this, Net Interest-Bearing debt at the end of the quarter stood at € 157m.



differences. Consequently, the equity ratio went down slightly to 42%.

## Balance Sheet

		Qtr1 2025	Qtr4 2024
Trade Working Capital	k€	208,464	205,196
Cash and cash equivalents	k€	33,484	28,906
Total assets	k€	581,801	586,258
Interest Bearing debt	k€	190,039	190,799
Total liabilities	k€	334,678	324,419
Equity	k€	247,122	261,839
Equity ratio	%	42%	45%
Net Interest Bearing Debt	k€	156,555	161,894

### Notes:

Interest Bearing Debt includes drawn debt facilities to non-related parties, as well as Lease Liabilities according to IFRS 16.

Net Interest Bearing Debt calculated as interest bearing debt subtracted for cash on balance sheet.

2024 figures updated to the final audited accounts and may differ from the Q4 2024 Interim Report.

- Total assets of the enlarged company at the end of Q1 2025 were € 582m, basically in line with year-end 2024.
- The equity similarly somewhat decreased as a result of a negative Total Other Comprehensive Result in Q1, partly driven by Fx translation

- Total Interest-Bearing Debt decreased slightly in Q1 to € 157m, reflecting the positive cash development. The current debt structure includes a € 180m bond loan placed on the Open Market of the Frankfurt Stock Exchange.
- The bond was issued on the 10th of October 2024 by O3 Holding GmbH with a five-year maturity, listed on the Open Market of the Frankfurt Stock Exchange (ISIN NO0013360552) and expected to be listed on the regulated market of the Oslo Stock Exchange in the course of 2025.
- The bond terms include a financial covenant of a minimum liquidity of € 10m, tested quarterly.
- The new Revolving Credit Facility of € 25m with DNB remained undrawn by the end of Q1 2025.

## Cash Flow

		Qtr1 2025	Qtr1 2024
Net cash flow from operating activities	k€	5,239	-8,426
Net cash flow from investing activities	k€	-878	-1,412
Net cash flow from financing activities	k€	662	-5,792
<b>Change in net cash &amp; cash equivalents</b>	<b>k€</b>	<b>5,023</b>	<b>-15,630</b>
Effect of exchange gains / (losses) on cash and cash equivalents	k€	-444	-126
Changes in cash and cash equivalents due to changes in the scope of consolidation	k€	0	3
Net cash & cash equivalents at the start of the period	k€	28,906	36,797
<b>Net cash &amp; cash equivalents at the close of the period</b>	<b>k€</b>	<b>33,484</b>	<b>21,044</b>

### Notes:

2024 figures updated to the final audited accounts and may differ from the Q4 2024 Interim Report.

- Our cash position ended at € 33m, with a € 5m cash inflow during Q1 2025.
- Trade Working Capital stabilized in Q1 2025, after significant increases last quarters coming from the acquired inventories via the dsm–firmenich transaction and subsequent specific inventory replenishment in Q4 2024 of raw fish oils during the fishing season.
- Additionally, another tranche of a subordinated Shareholder Loan that was granted by dsm–firmenich to the KD Pharma Group as part of the transaction also contributed to the cashflow from financing activities as well.



## Market Review

### Turbulent Market Environment Showing Signs of Stabilization

The past few years have seen unprecedented disruptions in the fish oil supply chain, driven by lower fishing yields and environmental factors that significantly increased raw material costs. These challenges have constrained market demand, as higher input costs have been passed through the supply chain, impacting both producers and consumers.

However, the situation appears to be improving. The most recent fishing season in Peru—one of the largest global sources of omega-3 fish oils—was strong, leading to a replenishment of global fish oil inventories. This has helped raw material prices return closer to their historical levels, easing some of the pricing pressures that have affected industry. As a result, core business areas within the KD Pharma Group and the broader sector are gradually adjusting to the new market conditions, with suppliers and customers recalibrating their strategies in response to a more stable pricing environment.

### Pharma Market Showing First Signs of Recovery after 2024

#### Headwinds

After experiencing significant growth over the past decade, the pharmaceutical omega-3 market is now maturing. In the United States, the icosapent ethyl market has encountered growing competition from generic alternatives, which has led to reduced investment in market promotion

and efforts to drive patient awareness. This has contributed to a more cautious approach in the sector, as companies navigate the implications of increased generic availability. Additionally, the increase in the number of generic competitors has led to more competitive market conditions as prices for the end product have dropped and established generic competitors needing to work through excess inventory.

Outside the US, the outlook is more promising. The originator secured national reimbursement for its icosapent ethyl pharmaceutical product in Greece in May 2024. In June 2025, an exclusive licensing and distribution partnership was established in Italy with a leading pharmaceutical player in the cardiovascular market to expand market access.

Additionally, following the wait-and-see pause in 2024—driven by pricing uncertainty post-Peru fishing season and demand disruptions such as the physician strike in South Korea—the omega-3 acid ethyl ester API market began showing signs of recovery in 2025, supported by solid anchovy catches in Peru's fishing season.

While these mark further positive developments, the impact on active pharmaceutical ingredient (API) demand is expected to materialize gradually over time, with underlying growth drivers of rising cardiovascular disease prevalence and increased therapeutic adoption remain.

## Nutra Market Continue to Demonstrate Resilience

Despite significant volatility in raw material costs last year, the nutraceutical omega-3 market remained relatively strong during this time. Demand for bulk fish oils has proven to be robust, with producers successfully passing on price increases to customers over time. This resilience has helped stabilize the market, ensuring continued supply and demand equilibrium. However, with raw material prices dropping, competitive pressure increases to adapt pricing as well.

Demand in the Nutra standard oil and concentrates markets picked up with more volume transacting, albeit at lower price points than seen in last year's high raw material price environment.

The finished dosage form (FDF) softgel segment continues to show solid performance. The company has seen strong growth in this category, benefiting from increased production capacity and solid demand from customers seeking high-quality omega-3 supplements. As consumers continue to prioritize health and wellness, the nutraceutical segment is expected to remain a key driver of industry stability, providing opportunities for further growth and expansion.

These market dynamics underscore the evolving landscape of the omega-3 industry, with challenges and opportunities shaping the strategies of key players. As KD Pharma Group continues to navigate these changes, its diversified portfolio and expanded capabilities position it well to capitalize on emerging trends and develop long-term growth and underscore the importance of extracting synergies from the dsm-firmenich Marine Lipids acquisition.



## Focus on Integrating dsm–firmenich’s Marine Lipids business

### Operational Integration

We are well advanced in the process of integrating dsm–firmenich’s Marine Lipids business which we acquired in late 2024. We expect all integration activities to be completed by the end of Q3 2025, except for the ERP migration in Peru and Canada, which is planned for Q1 2026.

We have started to leverage our new manufacturing network and capabilities to provide cost-effective and high-quality intermediates to our other manufacturing sites – this reduces our dependency on external suppliers. We have also started to execute on the planned consolidation of our manufacturing footprint in Europe. Following the receipt of the necessary regulatory approvals, we are also supplying former dsm–firmenich customers in New Zealand, China and Brazil.

### Product Registrations and Licenses

KD Pharma Group’s Q4 results did not include revenue for sales in some countries that dsm–firmenich served prior to closing due to the length of time it will take to transfer product registrations and licenses from dsm–firmenich to KD Pharma Group. These customers will continue to be served by dsm–firmenich until the registration changes are finalized. The timeline

for transferring these registrations is expected to take three to twelve months, depending on the country, and revenue is expected to begin to be recognized by KD Pharma Group over this period.



# Governance and Compliance

## Governance

We are fully committed to good corporate governance, including all necessary public disclosures. The KD Pharma Group has an Advisory Board at the MidCo Omega GmbH level (see our Corporate Organization Structure). Our Advisory Board consists of four members and its members collectively possess broad knowledge in the pharmaceutical and nutraceutical industries, as well as have a deep background in financial and auditing matters. The Advisory Board operates under the Rules of Procedure adopted by our shareholders. In addition, the KD Pharma Group operates under a set of Rules of Procedure for Management to ensure sufficient oversight of management's discharge of its duties and responsibilities.

KD Pharma Group also maintains an ad hoc committee to ensure that the confidential nature of inside information is properly maintained and timely published.

Good governance is deeply rooted in our corporate culture. The Management and the Advisory Board of the KD Pharma Group uphold the principles of modern corporate governance through policies and practices that promote trust, transparency, accountability and commitment.

## Compliance

We are committed to promoting high standards of ethical business conduct and compliance with all applicable laws, rules and regulations that govern our business. For example, we take anti-corruption, conflicts of interests, fair competition, ESG, supply chain regulations, human rights, data privacy, good corporate governance, trade sanctions, etc., very seriously. We have designated individuals to serve as the KD Pharma Group's Chief Compliance Officer as well as the Data Protection Officer to align our practices with industry standards and conform to applicable laws.

We operate in a highly regulated industry, and we are regularly inspected by government agencies as well as our customers. We maintain a library of operating procedures to help ensure that our business operations are conducted in accordance with good manufacturing practices. We also have administrative policies that promote a socially responsible work-place environment, including rules that are intended to deter insider trading.

## Financial Statements

O<sup>3</sup> Holding GmbH, Bexbach

Unaudited consolidated interim financial statement for the Period ending Q1 2025

O<sup>3</sup> Holding GmbH  
Am Kraftwerk 6  
66450 Bexbach



A. Unaudited consolidated statement of financial positions as of Q1 2025<sup>1</sup>

	Mar. 31, 2025	Dec 31th, 2024
	k€	k€
<b>Noncurrent assets</b>		
Goodwill	31,491	32,548
Other intangible assets	105,242	109,612
Property, plant and equipment	134,514	140,278
Other financial assets	4,214	4,226
Deferred taxes	2,849	3,413
	<b>278,311</b>	<b>290,078</b>
<b>Current assets</b>		
Inventories	219,751	216,794
Trade accounts receivable	35,944	30,863
Other financial assets	147	
Other receivables	11,939	17,439
Claims for income tax refunds	2,225	2,179
Cash and cash equivalents	33,484	28,906
	<b>303,490</b>	<b>296,180</b>
<b>Total assets</b>	<b>581,801</b>	<b>586,258</b>

<sup>1</sup> Further details see E.IV.

	Mar. 31, 2025	Dec 31th, 2024
	k€	k€
<b>Equity</b>		
Capital Stock	36	36
Capital reserves	348,926	348,926
Other reserves	-101,214	-92,036
Accumulated other comprehensive income	-379	5,147
<b>Equity attributable to shareholders of O<sup>3</sup> Holding GmbH</b>	<b>247,369</b>	<b>262,073</b>
<b>Non-Controlling Interest</b>	<b>-247</b>	<b>-234</b>
	<b>247,122</b>	<b>261,839</b>
<b>Noncurrent liabilities</b>		
Provisions for long-term employee benefits	1,399	1,416
Financial liabilities	235,196	230,222
Other liabilities	6,314	6,314
Deferred taxes	6,808	8,005
	<b>249,717</b>	<b>245,958</b>
<b>Current liabilities</b>		
Liabilities for short-term employee benefits	8,776	8,692
Other provisions	91	91
Financial liabilities	6,718	5,768
Trade accounts payable	47,231	42,461
Income tax liabilities	17,919	16,660
Other liabilities	4,226	4,788
	<b>84,961</b>	<b>78,461</b>
<b>Total equity and liabilities</b>	<b>581,801</b>	<b>586,258</b>



## B. Unaudited consolidated statement of comprehensive income Q1 2025<sup>2</sup>

	Q1/2025	Q1/2024
	k€	k€
<b>Net sales</b>	<b>73,631</b>	<b>53,373</b>
Cost of goods sold	-55,393	-40,786
<b>Gross profit</b>	<b>18,238</b>	<b>12,588</b>
Selling expenses	-7,579	-3,864
Research and development expenses	-569	-364
General administration expenses	-9,753	-5,013
Other operating income	2,368	68
Other operating expenses	-3,355	-1,466
<b>Earnings before financial result and taxes (EBIT)</b>	<b>-650</b>	<b>1,948</b>
Financial income	94	2,626
Financial expenses	-5,279	-6,450
<b>Financial result</b>	<b>-5,186</b>	<b>-3,824</b>
<b>Income before income taxes</b>	<b>-5,835</b>	<b>-1,875</b>
Income taxes	-3,364	-2,018
<b>Income after income taxes = net result</b>	<b>-9,199</b>	<b>-3,893</b>
Attributable to shareholders of O <sup>3</sup> Holding GmbH	-9,177	-3,863
Attributable to non-controlling interests	-22	-30

<sup>2</sup> Further details see E.V.

	Q1/2025	Q1/2024
	k€	k€
Changes in fair value of equity instruments measured at fair value	9	2
Income taxes	-1	0
<b>Other comprehensive income from equity instruments measured at fair value</b>	<b>7</b>	<b>2</b>
<b>Other comprehensive income that will not be reclassified subsequently to profit or loss</b>	<b>7</b>	<b>2</b>
Other comprehensive income (translation difference)	-5,545	3,515
Other comprehensive income at equity (translation difference)	0	0
<b>Other comprehensive income that may be reclassified subsequently to profit or loss</b>	<b>-5,545</b>	<b>3,515</b>
<b>Total other comprehensive income</b>	<b>-5,537</b>	<b>3,516</b>
Attributable to shareholders of O <sup>3</sup> Holding GmbH	-5,527	3,503
Attributable to non-controlling interests	-11	13
<b>Total comprehensive income</b>	<b>-14,737</b>	<b>-377</b>
Attributable to shareholders of O <sup>3</sup> Holding GmbH	-14,704	-360
Attributable to non-controlling interests	-32	-17

### C. Unaudited consolidated statement of changes in equity period Q1 2025<sup>3</sup>

	Capital stock	Capital reserves	Other reserves	Remeasurement of defined benefit plans	Currency Translation Difference	Accumulated other comprehensive income	Equity attributable to shareholders of O <sup>3</sup> Holding GmbH	Non-controlling interests	Total
	KE	KE	KE	KE	KE	KE	KE	KE	
<b>1. Jan. 2024</b>	<b>36</b>	<b>137,576</b>	<b>49,822</b>	<b>-32</b>	<b>-5,269</b>	<b>-5,301</b>	<b>182,133</b>	<b>127</b>	<b>182,260</b>
Equity transactions with owner						0	0		0
Cash capital increase						0	0		0
Non-cash capital increase						0	0		0
Change in scope of consolidation						0	0		0
Other changes			-431			0	-431		-431
Total comprehensive income			-3,863	1,659	3,245	3,246	-617	-265	-881
<i>Income after income taxes = Net income of the year</i>			-3,863			0	-3,863	-30	-3,893
Other comprehensive income				2	3,245	3,246	3,246	-235	3,011
<b>Mar. 31, 2024</b>	<b>36</b>	<b>137,576</b>	<b>45,528</b>	<b>-30</b>	<b>-2,024</b>	<b>-2,054</b>	<b>181,086</b>	<b>-138</b>	<b>180,948</b>
<b>Jan. 1, 2025</b>	<b>36</b>	<b>348,926</b>	<b>-92,036</b>	<b>-581</b>	<b>5,728</b>	<b>5,147</b>	<b>262,073</b>	<b>-234</b>	<b>261,839</b>
Equity transactions with owner						0	0		0
Cash capital increase						0	0		0
Non-cash capital increase						0	0		0
Change in scope of consolidation						0	0		0
Other changes						0	0		0
Total comprehensive income			-9,177	7	-5,534	-5,527	-14,704	-12	-14,716
<i>Income after income taxes = Net income of the year</i>			-9,177			0	-9,177	-22	-9,199
Other comprehensive income				7	-5,534	-5,527	-5,527	10	-5,517
<b>Mar. 31, 2025</b>	<b>36</b>	<b>348,926</b>	<b>-101,214</b>	<b>-573</b>	<b>194</b>	<b>-379</b>	<b>247,369</b>	<b>-247</b>	<b>247,122</b>

<sup>3</sup> For further details, see E.IV.

D. Unaudited consolidated statement of cash flows period Jan. 1, 2025 to Mar. 31, 2025<sup>4</sup>

	Q1/2025	Q1/2024
	k€	k€
Income after income taxes	-9,199	-3,893
Depreciation, amortization and impairment	7,962	3,660
Changes in provisions	188	139
Changes in deferred taxes	-605	-364
Other non-cash income and expenses	3,641	-2,040
Interest expenses/interest income reclassified	5,193	4,744
Decrease (increase) in inventories	-8,289	850
Decrease (increase) in trade accounts receivable	-5,890	-16,508
(Decrease) increase in trade accounts payable	5,354	2,222
Decrease (increase) in other operating receivables and income tax assets	6,453	-471
(Decrease) increase in other operating liabilities and income taxes	432	3,234
<b>Net cash provided by (used for) operating activities</b>	<b>5,239</b>	<b>-8,426</b>
(Cash outflow) for additions of property, plant, equipment and intangible assets	-965	-1,611
Interest received	87	199
<b>Net cash (used in) investing activities</b>	<b>-878</b>	<b>-1,412</b>

<sup>4</sup> For further details, see E.VI.

	Q1/2025	Q1/2024
	KE	KE
Repayment of financial liabilities	-578	-1,090
Cash outflow/inflow shareholder loan	5,400	0
Interest paid	-4,161	-4,702
<b>Net cash provided by financing activities</b>	<b>662</b>	<b>-5,792</b>
Net increase/decrease in cash and cash equivalents	5,023	-15,630
<b>Cash and cash equivalents at beginning of period</b>	<b>28,906</b>	<b>36,797</b>
Change in cash and cash equivalents due to changes in scope of consolidation	0	3
Change in cash and cash equivalents due to exchange rate movements	-444	-126
<b>Cash and cash equivalents at end of period</b>	<b>33,484</b>	<b>21,044</b>
<b>Supplementary information on Cash Flows from Operating Activities</b>		
Income taxes paid (less refunds)	-281	-1,738

## E. Notes to the condensed unaudited consolidated financial statements for the period Jan. 1, 2025 to Mar. 31, 2025

### E.I General information

Together with its subsidiaries, O<sup>3</sup> Holding GmbH (O<sup>3</sup>) is engaged in the production and sale of products based on Omega-3 fatty acids in the nutraceutical sector and for pharmaceutical applications. The Company is domiciled in Bexbach, Germany, and is entered in the commercial register at the Saarbrücken Local Court under no. HRB 103555.2. The accompanying unaudited condensed consolidated interim financial statements were authorized for issue by management on July 11, 2025. The interim report has not been audited. The interim report does not include all the information required for a complete set of year-end financial statements and should therefore be read in conjunction with the consolidated financial statements for 2024.

### E.II Significant accounting and valuation methods

The condensed interim consolidated financial statements of O<sup>3</sup> for the 1st quarter of the 2025 financial year ending March 31, 2025 have been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the European Union (EU). The interim report has not been audited. The interim report does not include all the information required for a complete set of year-end financial statements and should therefore be read in conjunction with the consolidated financial statements for 2024.

All amounts in the notes and tables are stated in Euros unless otherwise stated. Both individual figures and totals represent the value with the smallest rounding difference. When adding up the individual figures shown, small differences may therefore occur compared to the totals shown.

The accounting policies applied in the condensed interim consolidated financial statements are the same as those applied in the last consolidated financial statements as of December 31, 2024, except for the following provisions.

The following agreements of the International Accounting Standards Board (IASB) adopted by the EU are mandatory for the first time in the 2025 financial year:

Standard / Interpretation	
IAS 21	Currency conversion in the absence of exchangeability

The regulations to be applied for the first time in the 2025 financial year did not result in any significant changes in accounting for the condensed interim consolidated financial statements. No provisions were applied prematurely.

The consolidated financial statements are prepared based on historical acquisition or production costs, unless the accounting and valuation principles explained below require otherwise. The consolidated income statement included in the consolidated statement of comprehensive income has been prepared using the cost of sales method.

The estimates and assumptions underlying the preparation of the financial statements in accordance with IFRS affect the measurement of assets and liabilities, the disclosure of contingent assets and liabilities at the respective balance sheet dates and the amount of income and expenses for the reporting period. Although these assumptions and estimates are made to the best of management’s knowledge based on current events and measures, actual results may ultimately differ from these estimates. Further information on estimates, assumptions and discretionary decisions can be found in section E.IV. Estimates and discretionary decisions in the consolidated financial statements as of December 31, 2024.

The current debt structure includes a € 180m bond loan placed on the Open Market of the Frankfurt Stock Exchange.

The bond was issued on the 10th of October 2024 by O3 Holding GmbH with a five-year maturity, listed on the Open Market of the Frankfurt Stock Exchange (ISIN NO0013360552) and expected to be listed on the regulated market of the Oslo Stock Exchange in the course of 2025.



The bond terms include a financial covenant of a minimum liquidity of € 10m, tested quarterly.

In January, O<sup>3</sup> entered into a Revolving Credit Facility of € 25m with DNB (term 5 years) which remained undrawn by the end of Q1 2025.

Adjusted EBITDA in Q1 amounted to k€ 10,014. Reported Adjusted EBITDA for the quarter came in at k€ 8,337.

### E.III Consolidation

As of March 31, 2025, O<sup>3</sup> included fourteen subsidiaries (prior year: fourteen) in its consolidated financial statements. Three subsidiaries are individually and collectively immaterial on the consolidated balance sheet date and one of which is also expected to be immaterial in the future. A list of the consolidated companies can be found in section E.II.3.b. in the consolidated financial statements as of December 31, 2024.

### E.IV Notes on individual items in the consolidated financial statement

#### Intangible assets

Intangible assets stood at k€ 105,242 at the end of Q1 2025, a decrease of k€ 4,370 reflecting normal amortizations.

#### Property, plant and equipment and assets under construction

The property, plant and equipment as per Mar. 2025 amounted to k€ 134,514, a decrease of k€ 5,765 reflecting normal depreciation.

### Inventories

The O<sup>3</sup> Group's inventories comprise the following:

in k€	31/03/2025	31/12/2024
Raw materials and supplies	60,836	60,629
Unfinished products	72,500	60,823
Finished Products	86,094	95,022
Advance payments	321	320
<b>Total</b>	<b>219,751</b>	<b>216,794</b>

### Other receivables

Other receivables were k€ 11,939 at the end of the first quarter 2025. This reflects a decrease of k€ 5,500 as some VAT tax reimbursements outstanding at year end was received during the quarter.

### Cash and cash equivalents

Cash and cash equivalents were valued as follows in the following currencies:

in k€	31/03/2025	31/12/2024
EUR	14,060	19,817
USD	14,866	7,612
CHF	275	181
GBP	404	647
PEN	2,580	71
CAD	1,015	165
NOK	283	413
<b>Total</b>	<b>33,484</b>	<b>28,906</b>

#### Financial liabilities

The O3 Holding Group holds corporate bonds listed on the Open Market of the Frankfurt Stock Exchange (ISIN NO0013360552). These non-current financial liabilities are also secured by liens and assignments of collateral and stipulates certain financial indicators with the creditors that were adhered to during the financial quarter under review.

In January 2025, the Group received a shareholder loan from DSM Nederland B.V. in the amount of k€ 5,400.

Beginning of January 2025, O<sup>3</sup> entered into a Revolving Credit Facility of € 25m with DNB (term 5 years) which remained undrawn by the end of Q1 2025. The agreed interest rate is the 3-month Euribor plus a maximum margin of 4%, depending on the debt ratio.

#### Trade accounts payable

Trade payables increased by k€ 4,770 compared to the balance sheet date of 31.12.2024 to a total of k€ 47,231 due to increased raw material purchases, among

other things.

## E.V Notes on individual items in the income statement

### Revenue

Revenue is almost exclusively generated from the supply of products. It is allotted to the following product categories:

in k€	Q1/2025	Q1/2024
Pharmaceuticals	6.939	19.654
Nutraceuticals	66.692	33.719
<b>Total</b>	<b>73.631</b>	<b>53.373</b>

Revenue was generated in the following markets:

in k€	Q1/2025	Q1/2024
North America	48.816	29.495
Europe	13.601	19.253
Asia	9.412	4.470
Other	1.802	155
<b>Total</b>	<b>73.631</b>	<b>53.373</b>

### Cost of Sales

Cost of sales comprised the following components:

in k€	Q1/2025	Q1/2024
Cost of materials	35.758	27.517
Personnel costs	9.719	6.799
Utilities and other rent expenses	3.362	2.092
Amortization/Depreciation	4.619	2.793
Maintenance and waste disposal	1.147	874
Other Costs	788	711
<b>Total</b>	<b>55.393</b>	<b>40.786</b>

### Selling and distribution costs

Selling and distribution expenses included the following cost components:

in k€	Q1/2025	Q1/2024
Cost of goods sold	2.489	1.331
Personnel costs	1.322	823
Advertising expenses	611	533
Amortization/Depreciation	1.952	403
External services	144	141
Legal and consulting costs	231	2
Other Costs	828	632
<b>Total</b>	<b>7.579</b>	<b>3.864</b>

The increase in amortization is largely due to the regular amortization of customer relationships from the acquisition of the Marine Lipids Business in September 2024.

Also the acquisition of the dsm–firmenich Marine Lipids business clearly increased the size of the Group.

### Income taxes

Compared to the previous period, income taxes increased by k€ 1,346 from k€ 2,018 to k€ 3,364.

### Other comprehensive income (translation difference)

Exchange rate translation differences related to the consolidation of Balance sheet items in foreign entities accounted for under Other comprehensive income came in at a loss of k€ 5,545 this quarter. These differences are accounted for directly in Equity. Main driver here is the weakening of the USD versus the EUR in the reporting period.



## E.VI Statement of cash flows

Net cash inflow for the quarter Q1 2025 was k€ 5,023.

It reflects positive cash from operating activities from operating activities during Q1 2025 of k€ 5,419, mainly driven by positive operating cash performance of k€ 14,244 excluding TWC, outpacing a net cash increase in Trade Working Capital of k€ 8,825.

The net cash outflow from investing activities of k€ 878 for Q1 2025 mostly reflects the continuation of investments which we started in 2024.

Net cash inflow from financing activities was k€ 481 for Q1 2025, mostly consisting of the proceeds from a shareholder loan of k€ 5,400 netting out the net cash interest expenses.

## E.VII Financial instruments

The O<sup>3</sup> Group has numerous financial instruments that are not measured at fair value in the consolidated balance sheet. Due to the predominantly short maturities, the fair values of trade receivables and payables, other financial assets and liabilities and cash and cash equivalents do not differ significantly from the carrying amounts. The same applies to the Group's financial liabilities due to their variable interest rates.

## E.VIII Segment reporting

Segment reporting of O<sup>3</sup> follows the approach taken for internal management reporting. In the O<sup>3</sup> Group, the management board (as the chief operating decision maker) decides on the allocation of resources to the operational segments and monitors their performance.

The O<sup>3</sup> group is managed via its operational segments Pharma and Nutra, which are also the reportable segments.

The Pharma segment concentrates on highly concentrated Omega 3 products with proven clinical effectiveness, for example for the treatment of patients with very high triglyceride. The products are based on a certain ratio of the Omega3 molecules DHA and EPA (Lovaza, Lotriga) or a highly concentrated Omega3 product containing EPA (Vascepa, Epadel).

The Nutra segment mainly encompasses Omega 3 products with lower to medium concentrations in formulations with a variety of health-related claims.

The accounting policies applied in segment reporting are based on the IFRS applied in the consolidated financial statements. Because there were no transactions between the segments and all expenses and income were allocated to the two segments, segment reporting does not contain any reconciliation column for the corresponding Group figures.

Adjusted EBITDA is the key performance parameter applied by the O3 Group. This parameter is not defined in the International Financial Reporting Standards. Within the O3 Group, adjusted EBITDA is defined as earnings before income taxes, financial result, amortization and depreciation, impairments, foreign exchange gains and losses, restructuring expenses, extraordinary income and expenses as well as off-period expenses and income.

The following table presents the key performance parameters used to assess the performance of the segments within the O3 Group:

Segment information	Pharma		Nutra		O <sup>3</sup> Group	
in k€	Q1/2025	Q1/2024	Q1/2025	Q1/2024	Q1/2025	Q1/2024
Revenues of segment =	6,939	19,654	66,692	33,719	73,631	53,373
Revenues with external						
Adjusted EBITDA	-4,423	3,183	14,436	4,807	10,014	7,990
Adjusted EBITDA Marge	-63.7%	4.8%	21.6%	14.3%	13.6%	15.0%

The following table presents additional performance indicators according to region:

in k€	North America	Germany	Rest of Europe	Asia	Other regions	O <sup>3</sup> Group
Revenues Q1/2025	48.816	5.424	8.177	9.412	1.802	73.631
Non-current assets as of 31 Mar 2025	74.316	50.366	123.291	–	30.338	278.311

in k€	North America	Germany	Rest of Europe	Asia	Other regions	O <sup>3</sup> Group
Revenues Q1/2024	29.495		19.253	4.470	155	53.373
Non-current assets as of 31 Mar 2024	50.474	50.924	121.789	–	–	223.186

There was one customer in the Nutra segment accounting for 12% of the sales of the O3 Group in Q1 2025. In Q1 2024, one customer in the Pharma segment accounted for 14% of the sales of the O3 Group.

Adjusted EBITDA is reconciled with earnings before taxes in the following table:

A net total of k€ 1,677 costs were adjusted from the reported accounting EBITDA to come to the adjusted EBITDA for Q1 2025. Main component of the

in K-€	Q1/2025	Q1/2024
<b>Adjusted EBITDA</b>	<b>10,014</b>	<b>7,990</b>
Consulting fees and transaction related expenses <sup>1)</sup>	-932	–
Legal one-offs and similar expenses <sup>2)</sup>	-528	-138
Restructuring <sup>3)</sup>	-15	-957
Miscellaneous <sup>4)</sup>	-203	8
<b>EBITDA (accounting before Fx gains/losses)</b>	<b>8,337</b>	<b>6,902</b>
Foreign exchange gains and losses	-1,025	-1,294
<b>EBITDA (accounting)</b>	<b>7,312</b>	<b>5,609</b>
Depreciation & Amortization	-7,962	-3,660
<b>EBIT</b>	<b>-650</b>	<b>1,948</b>
Financial result	-5,186	-3,824
<b>EBT Earning before taxes</b>	<b>-5,835</b>	<b>-1,875</b>

1) Reflects mainly consulting fees as well as personnel payments and other expenses related to financing and M&A activities.

2) Reflects legal expenses due to the course of lawsuits and similar legal proceedings.

3) Reflects additions to restructuring provisions and similar expenses related to the consolidation of manufacturing operations

4) Reflects one-time expenses including bad debt allowances, losses from the disposal of assets, inventory

adjustment relates A net total of k€ 1,677 costs were adjusted from the reported accounting EBITDA to come to the adjusted EBITDA for Q1 2025. Main component of the adjustment relates to consulting fees and other costs of the carve out and integration of the systems of the acquired Marine Lipids business.

The remaining adjustments mainly relate to legal expenses due to the course of lawsuits and similar legal proceedings and the restructuring of the UK organization and related costs resulting from the integration of O3 manufacturing in other sites in our expanded manufacturing network.

#### E.IX Related party disclosure

The group of related parties includes all direct or indirect shareholders of O<sup>3</sup> Holding GmbH that have a controlling or decisive influence on the Group, the unconsolidated subsidiaries, associates and key management. This also includes the key management employees due to the assumption of Group management and monitoring functions regarding the related parties.

The key management group consists of the CEO of O<sup>3</sup> Holding's Group activities, as well as the Business and Functional leaders reporting directly into the CEO. The Business leaders include the CEO of KD Nutra, VP Global Pharma Sales and Global Purchasing. The Functional leaders comprise the CFO, the Chief Business Officer (CBO), the VP Global Operations, VP Global HR, the VP Global Quality & Regulatory, and the Global General Counsel.

Following the change to the shareholder structure in September 2024, the direct parent company of O<sup>3</sup> Holding GmbH is MidCo Omega GmbH. Its direct shareholders are Mellifera Neunte Beteiligungs GmbH, DSM Nederland BV and AcquicoOmega GmbH. The shares of Mellifera Neunte Beteiligungs GmbH are held by Acquico Omega GmbH. TopCo Omega GmbH is the ultimate parent company of O<sup>3</sup> Holding GmbH. The shares in TopCo Omega GmbH are largely held by fund companies of the Capiton Group.

The following table contains a summary of the transactions with related parties:

in k€	Transactions in the period under review (income statement)			Trade receivables (payables)	Loan receivables (payables) incl. Interest	Cash/non-cash contribution
	Revenues/ operating income	Operating expenses	Interest income (expense)			
Q1/2025						
Acquico Omega GmbH	–	–	–	-6	–	–
Trigal Pharma GmbH	–	–	–	–	368	–
DSM B.V. and subsidiaries	5.628	-3.378	-994	-5.758	-51.585	–
Total Q1/2025	5.628	-3.378	-994	-5.764	-51.216	–
Q1/2024						
Trigal Pharma GmbH	–	–	4	–	342	–
Total Q1/2024	–	–	4	–	342	–

#### E.X Events after the reporting period

In April 2025 we received an additional shareholder loan from DSM Nederland B.V. in the amount of € 10.5 Mio.

At the beginning of April 2025, it was decided to transfer Omega3 production from the UK site to other KD sites and to initiate a partnering/sale process for the UK site for the CDMO business.

## Risk Factors

Some key risk factors relevant to the business and financial outlook of KD Pharma Group include the following:

### Supply Chain & Raw Material Volatility

The company's operations rely heavily on the availability and pricing of fish oil and other marine-based raw materials. The market has experienced significant fluctuations in recent years, largely driven by tightening fishing quotas, environmental factors like El Niño, and rising global demand for fish oil. While the latest fishing season in Peru has helped stabilize supply, any future disruptions or unfavorable quota changes could lead to raw material shortages and price spikes.

Additionally, political and economic instability in key sourcing regions, such as Peru and Morocco, may present logistical challenges and impact the cost structure.

### Competitive Market Environment

The KD Pharma Group operates in a highly competitive sector, with pressure from both global CDMO players and niche specialists. Large pharmaceutical and nutrition companies with in-house manufacturing capabilities, as well as emerging low-cost competitors from China and India, could continue to put downward pressure on pricing. The launch of generic alternatives, particularly in the icosapent ethyl API segment, has intensified market dynamics, leading to pricing erosion and potential loss

of market share.

### Risks Related to the Integration of dsm-firmenich's Marine Lipids Business

The ongoing integration of the acquired marine lipids business introduces operational and financial risks. Challenges may arise in harmonizing production processes across multiple sites, optimizing supply chains, and fully realizing anticipated synergies. If the integration process encounters delays or unforeseen complications, it could lead to inefficiencies, increased costs, or disruptions in customer supply. Additionally, the anticipated cost savings and operational advantages from consolidating manufacturing at the Peru and Mulgrave sites may take longer to materialize than initially projected.

### Macroeconomic & Geopolitical Uncertainty

The current global economic climate remains uncertain, with inflationary pressures, rising interest rates, geopolitical tensions, tariffs and other trade barriers affecting supply chains and market demand. A key risk is the potential for new tariffs and trade restrictions under the US administration's evolving trade policy and other governments' reactions to them, which could impact the cost competitiveness of products manufactured in Canada and Europe for the US market. Any new protective measures, such as increased import duties or regulatory barriers, could reduce margins and limit access to key customer segments. Additionally, inflationary pressures on input costs may not always be fully passed on to customers, putting margins under pressure.



## Financial & Liquidity Risks

The company's refinancing through bond issuance has improved its capital structure, but exposure to interest rate fluctuations and market liquidity risks remain. The floating rate nature of the bonds means that rising interest rates could increase debt servicing costs. Additionally, any delays or setbacks in realizing expected cost synergies from the integration of dsm-firmenich's business could put short-term financial performance under pressure.

## Pro Forma Information

The Pro Forma Information in this Interim Report is presented for illustrative purposes only and may not reflect the actual results of operations of the KD Pharma Group following the completion of the dsm-firmenich Transaction. In the past, the KD Pharma Group and dsm-firmenich have operated their respective businesses separately and there are no consolidated results including dsm-firmenich prepared before the planned date for the completion of the dsm-firmenich Transaction on 30 September 2024 available for the KD Pharma Group as the results of dsm-firmenich will be consolidated with the KD Pharma Group from such date onwards. The pro forma financial and other information included in this Interim Report (the "Pro Forma Information") has been prepared in order to provide an estimate what our results of operations would have been if we had been operating as a combined group. The Pro Forma Information has not been audited by

any independent auditor, is presented for illustrative purposes only and is not necessarily indicative of the Company's actual results of

operations as a combined company during the periods presented in the Pro Forma Information. Moreover, the Pro Forma Information does not purport to project the future results of operations of the KD Pharma Group. The Pro Forma Information has been prepared based on unaudited internal management accounts provided by dsm-firmenich and given the fact that the business acquired is an integral part that is carved out of the larger business of dsm-firmenich AG, are not reconcilable to the audited external financial statements of the dsm-firmenich AG entities. Therefore, certain preliminary assumptions, normalization adjustments, consolidation assumptions, and estimates that the KD Pharma Group believes to be reasonable under the current circumstances, have been made in preparing the Pro Forma Information. The actual impacts of the dsm-firmenich Transaction may materially differ from the assumptions used in the Pro Forma Information. In addition, the Pro Forma Information does not reflect any expected cost savings, synergy benefits or future integration costs that are expected to be generated or incurred.

## Impairment Risks

Our operating results can vary significantly as a result of the impairment of goodwill and other intangible assets. Under IFRS, we are required to annually test our recorded goodwill and to assess the carrying values of other intangible assets when impairment indicators exist. As a result of such tests, we may be required to recognize impairment losses in our income statement if the carrying value is in excess of the fair value. Factors that could trigger an

impairment of such assets include the underperformance of our business relative to projected future operating results, negative industry developments or economic trends, including changes in borrowing rates or weighted average

cost of capital, applicable tax rates or changes in working capital. For example, we are currently in the process of evaluating the potential sale of production plants or a part thereof, which may result in impairment losses for some of the related assets. Should we have to book any impairment losses, this could have a material adverse effect on our business, results of operations and financial condition, and ultimately our ability to fulfil our obligations under the Bond Terms, as well as the market price and value of the Bonds.

Bexbach, 11th of July, 2025

Oscar Groet



Via Campagna 30 • 6934 Bioggio • Switzerland  
[info@kdpharmagroup.com](mailto:info@kdpharmagroup.com)